BioLife Solutions Q2 Revenue Jumps 21% to $28.5M; Repligen Merger Announced at $31/Share
BLFS sits 90% above its 52-week low of $17.86.
Summary
BioLife Solutions reported Q2 2026 revenue of $28.5M (+21% YoY) and net income of $45.1M, boosted by a tax valuation allowance release. The company also disclosed a pending acquisition by Repligen at $31/share, valuing the company at $1.5B.
Key Events · Earnings and Guidance · BLFS
-
Q2 Revenue Up 21% to $28.5M
Revenue grew to $28.5 million in Q2 2026, up 21% from $23.4 million a year ago, driven by strong demand for biopreservation media. Six-month revenue reached $56.0 million, a 23% increase.
-
Net Income Boosted by $42.4M Tax Benefit
Net income surged to $45.1 million in Q2, primarily due to a $42.4 million release of deferred tax valuation allowance, reflecting sustained profitability. Operating income was $1.7 million.
-
Repligen Merger Announced at $31/Share
On July 21, 2026, BioLife entered into a definitive merger agreement with Repligen, which will acquire all outstanding shares for $11.25 cash and 0.1442 shares of Repligen per BioLife share, implying a $31.00 per share value and $1.5 billion enterprise value.
-
Term Loan Fully Repaid
The company repaid its remaining term loan balance and a $1.2 million balloon payment upon maturity on June 1, 2026, leaving no long-term debt on the balance sheet.
Analysis · BLFS · Industrial Applications And Services
A standout quarter for BioLife Solutions saw revenue climb 21% year-over-year to $28.5 million, fueled by its leading biopreservation media products. The bottom line got an extraordinary lift from a $42.4 million deferred tax valuation allowance release, which transformed a modest operating profit into $45.1 million in net income. Even more consequential, the company disclosed a definitive agreement to be acquired by Repligen for $31 per share in cash and stock — a deal that values BioLife at $1.5 billion and will take the company private. The merger, announced July 21, is expected to close in Q4 2026, subject to shareholder and regulatory approvals. This 10-Q offers the first detailed look at the financial health of the business ahead of that transaction.
At the time of this filing, BLFS was trading at $33.93 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $17.86 to $34.34. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.